- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Daniel Mullins, PhD: How Biosimilars Are Impacting Costs
Daniel Mullins, PhD, chair of pharmaceutical health services research at the School of Pharmacy, University of Maryland, discusses how biosimilars are impacting the cost of care.
Transcript
Biosimilars are a real game-changer. In the same way that we've seen a reduction in price as we see traditional medicines going to branded, we're seeing the same thing with biosimilars.
If you would have asked me what am I potentially worried about, if you look back to the literature, when generics first came out to the market in the more expedited role, there was a generic drug scandal, and if anything were to happen where there were a biosimilar that was used that we found out really wasn't as good as the originator biologic, that could set biologics back.
But short of that, I really do believe that this is going to be good for the American public.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Q&A: Dr Kimberly Maxfield Explains How BsUFA III Will Advance the US Biosimilar Industry
December 20th 2023At AMCP Nexus, Kimberly Maxfield, PhD, pharmacologist at the FDA, delved into how the third reauthorization of the Biosimilar User Fee Act (BsUFA III) will shape the American biosimilar market and improve development efficiency over the next few years.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
